Research Analysts Issue Forecasts for PRQR FY2026 Earnings

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Stock analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for ProQR Therapeutics in a research report issued to clients and investors on Wednesday, May 13th. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will earn ($0.44) per share for the year, down from their prior forecast of ($0.43). The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.53) per share.

ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). The company had revenue of $2.35 million during the quarter, compared to the consensus estimate of $5.19 million. ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.

A number of other research firms also recently issued reports on PRQR. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Oppenheimer initiated coverage on ProQR Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $9.00 price objective for the company. Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Thursday, April 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Tuesday, April 21st. Finally, Wall Street Zen upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, March 14th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, ProQR Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

ProQR Therapeutics Stock Down 2.9%

Shares of ProQR Therapeutics stock opened at $1.65 on Friday. The company has a market cap of $173.84 million, a PE ratio of -3.59 and a beta of 0.08. The business has a 50 day moving average of $1.70 and a 200 day moving average of $1.86. ProQR Therapeutics has a 52 week low of $1.33 and a 52 week high of $3.10.

Institutional Investors Weigh In On ProQR Therapeutics

Institutional investors have recently modified their holdings of the business. Aberdeen Group plc boosted its position in shares of ProQR Therapeutics by 24.2% during the third quarter. Aberdeen Group plc now owns 2,298,823 shares of the biopharmaceutical company’s stock valued at $4,896,000 after buying an additional 448,475 shares during the last quarter. Privium Fund Management B.V. boosted its position in shares of ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after buying an additional 359,475 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of ProQR Therapeutics by 14.9% during the third quarter. BNP Paribas Financial Markets now owns 139,594 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 18,100 shares during the last quarter. Ikarian Capital LLC boosted its position in shares of ProQR Therapeutics by 67.2% during the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock valued at $3,014,000 after buying an additional 600,000 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its position in shares of ProQR Therapeutics by 43.1% during the fourth quarter. Boothbay Fund Management LLC now owns 355,283 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 106,993 shares during the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.